We are live on ! Find out more
JBIO

Jade Biosciences
JBIO

68 hedge funds and large institutions have $803M invested in Jade Biosciences in 2022 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 16 increasing their positions, 22 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

130% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 10

85% more capital invested

Capital invested by funds: $434M → $803M (+$369M)

24% more funds holding

Funds holding: 55 → 68 (+13)

14% more funds holding in top 10

Funds holding in top 10: 7 → 8 (+1)

0.03% more ownership

Funds ownership: 3.15% → 3.18% (+0.03%)

27% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 22

Holders
68
Holders Change
+13
Holders Change %
+23.64%
% of All Funds
1.09%
Holding in Top 10
8
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+14.29%
% of All Funds
0.13%
New
23
Increased
16
Reduced
22
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
OCA
Octagon Capital Advisors
New York
+$12.9M
2
GPP
Great Point Partners
Connecticut
+$7.85M
3
SCM
Soleus Capital Management
Connecticut
+$4.5M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$3.63M
5
TCM
TCG Crossover Management
California
+$2.53M

Top Sellers

1
CAM
Cormorant Asset Management
Massachusetts
-$7.75M
2
AVLSA
Atlas Venture Life Science Advisors
Massachusetts
-$6.44M
3
LCM
Lynx1 Capital Management
Puerto Rico
-$4.58M
4
BlackRock
BlackRock
New York
-$2.23M
5
VA
VR Adviser
New York
-$1.78M
Name Holding Trade Value Shares
Change 		Change in
Stake
Invesco
26
Invesco
Georgia
$2.13M +$1.51M +2,074 New
Skandinaviska Enskilda Banken (SEB)
27
Skandinaviska Enskilda Banken (SEB)
Sweden
$1.56M -$63.9K -88 -5%
NFGH
28
Nan Fung Group Holdings
Hong Kong
$1.48M +$1.05M +1,446 New
N
29
Nuveen
North Carolina
$1.09M +$44.3K +61 +6%
SCM
30
Silverarc Capital Management
Massachusetts
$1.08M +$765K +1,054 New
D.E. Shaw & Co
31
D.E. Shaw & Co
New York
$864K -$99.5K -137 -14%
Bank of New York Mellon
32
Bank of New York Mellon
New York
$823K +$11.6K +16 +2%
BFM
33
Boothbay Fund Management
New York
$756K -$206K -284 -28%
Charles Schwab
34
Charles Schwab
California
$722K +$18.1K +25 +4%
Ensign Peak Advisors
35
Ensign Peak Advisors
Utah
$621K +$440K +606 New
Two Sigma Investments
36
Two Sigma Investments
New York
$619K +$439K +604 New
Swiss National Bank
37
Swiss National Bank
Switzerland
$607K +$429K +591 New
PL
38
Parkwood LLC
Ohio
$602K -$16.7K -23 -4%
CCMU
39
Cheyne Capital Management (UK)
United Kingdom
$555K +$393K +541 New
Renaissance Technologies
40
Renaissance Technologies
New York
$530K +$375K +517 New
AA
41
ALPS Advisors
Colorado
$489K +$346K +477 New
NCM
42
Nantahala Capital Management
Connecticut
$460K +$326K +449 New
RhumbLine Advisers
43
RhumbLine Advisers
Massachusetts
$417K +$2.18K +3 +0.7%
T. Rowe Price Associates
44
T. Rowe Price Associates
Maryland
$387K +$274K +378 New
TOCUITCONY
45
Trustees of Columbia University in the City of New York
New York
$386K +$274K +377 New
California State Teachers Retirement System (CalSTRS)
46
California State Teachers Retirement System (CalSTRS)
California
$325K +$155K +213 +205%
CS
47
Credit Suisse
Switzerland
$266K +$187K +258 +25,800%
State of Wisconsin Investment Board
48
State of Wisconsin Investment Board
Wisconsin
$251K +$178K +245 New
OWP
49
Old Well Partners
North Carolina
$237K +$168K +231 New
New York State Common Retirement Fund
50
New York State Common Retirement Fund
New York
$225K -$726 -1 -0.5%
1
2
3 4

JBIO Hedge Fund Activity: Q4 2022 in Review

68 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Jade Biosciences (JBIO) for Q4 2022, worth a combined $803M — up 85% from $434M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new JBIO positions and 10 closed out — a net gain of 13 holders — while 16 added to existing stakes and 22 trimmed.

The largest buyer was Octagon Capital Advisors, opening a new position worth an estimated $12.9M. The largest seller was Cormorant Asset Management, cutting an estimated $7.75M.

  • 68 institutional investors held Jade Biosciences (JBIO) as of Q4 2022, up from 55 in Q3 2022.
  • Funds reported $803M of Jade Biosciences stock for Q4 2022, up 85% quarter-over-quarter.
  • 23 funds opened new Jade Biosciences positions in Q4 2022 and 10 closed out, a net change of +13 holders.
  • The largest Jade Biosciences buyer in Q4 2022 was Octagon Capital Advisors, an estimated $12.9M added.
  • The largest Jade Biosciences seller in Q4 2022 was Cormorant Asset Management, an estimated $7.75M sold.

Based on aggregated 13F filings for Q4 2022.